Artiva Biotherapeutics, Inc. (ARTV) Price & Analysis

Compare

46 Followers

ARTV Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.47 - $17.31

Previous CloseN/A

Volume23.16K

Average Volume (3M)132.39K

Market Cap

$69.37M

Enterprise Value-$92.33M

Total Cash (Recent Filing)$142.37M

Total Debt (Recent Filing)$13.22M

Price to Earnings (P/E)―

Beta0.94

Next Earnings

Nov 18, 2025

EPS Estimate

-0.87

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.87

Shares Outstanding24,425,762

10 Day Avg. Volume56,259

30 Day Avg. Volume132,389

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-1.33

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda1.16

Forecast

1Y Price Target

$16.00

Price Target Upside389.30% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe FDA cleared the Phase IIa IND without requiring patient hospitalization, offering initial validation of AlloNK's value.

FDA DesignationIn February 2024, AlloNK received FDA fast track designation for the treatment of lupus nephritis combined with RTX/OBI, which is viewed favorably as it will streamline clinical development and regulatory interactions.

Financial PositionFinancially, the company is well-positioned, having reported a strong cash position which could fund operations into 2027, encompassing key clinical data milestones.

Bears Say

Enrollment ProgressEnrollment changes and generating small datasets across indications don't live up to the initial bar set by Schett.

Market UncertaintyThe target price is being adjusted to reflect broader market uncertainty.

Artiva Biotherapeutics, Inc. News

Artiva Biotherapeutics files $300M mixed securities shelf

17:17 EDT Artiva Biotherapeutics (ARTV) files $300M mixed securities shelf Published first on TheFly – the ultimate source...

24d ago

ARTV

Artiva Biotherapeutics Reports Progress in Clinical Trials

Artiva Biotherapeutics, Inc. ( ($ARTV) ) has released its Q2 earnings. Here is a breakdown of the information...

1d ago

ARTV

Positive Buy Rating for Artiva Biotherapeutics, Inc. Driven by Promising AlloNK Cell Therapy Developments

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Artiva Biotherapeutics, Inc.,...

23d ago

ARTV

Buy Rating Affirmed for Artiva Biotherapeutics Amid Promising AlloNK Data and Strong Financial Position

Needham analyst Gil Blum maintained a Buy rating on Artiva Biotherapeutics, Inc. today and set a price target...

23d ago

ARTV

Artiva Biotherapeutics Approves Equity Plan Amendment

Artiva Biotherapeutics, Inc. ( ($ARTV) ) has shared an announcement. On June 24, 2025, Artiva Biotherapeutics, Inc. held...

2M ago

ARTV

Promising Advancements and Financial Strength Position Artiva Biotherapeutics for Significant Upside

Artiva Biotherapeutics, Inc. (ARTV) has received a new Buy rating, initiated by H.C. Wainwright analyst, Emily Bodnar. Emily...

3M ago

ARTV

Artiva Biotherapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar assumed coverage of Artiva Biotherapeutics (ARTV) with a Buy rating and $12 price...

3M ago

ARTV

Artiva Biotherapeutics announces new, long-term data for AlloNK combination

Artiva Biotherapeutics (ARTV) announced new longer-term Phase 1/2 data demonstrating durable responses for AlloNK in combination with rituximab...

4M ago

ARTV

Artiva Biotherapeutics Reports Q1 2025 Progress

Artiva Biotherapeutics, Inc. ( ($ARTV) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

ARTV

Artiva Biotherapeutics: Strategic Delay and Expanded Research Justify Buy Rating

Needham analyst Gil Blum maintained a Buy rating on Artiva Biotherapeutics, Inc. (ARTV – Research Report) today and...

4M ago

ARTV

Artiva Biotherapeutics, Inc.: Strategic Advancements and Market Potential in Biotherapeutics Highlighted by Phase IIa Trial Initiation and FDA Clearance

Tyler Van Buren, an analyst from TD Cowen, has initiated a new Buy rating on Artiva Biotherapeutics, Inc....

4M ago

ARTV

Artiva Biotherapeutics reports Q1 EPS (83c) vs. ($17.24) last year

“We are encouraged by our early experience with AlloNK in autoimmune disease. We have initiated regulatory submissions globally...

4M ago

ARTV

Artiva Biotherapeutics sees cash runway into 2Q27

As of March 31, 2025, Artiva had cash, cash equivalents, and investments of $166.0 million which is expected...

4M ago

ARTV

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

5M ago

BMY

ARTV

ARTV FAQ

What was Artiva Biotherapeutics, Inc.’s price range in the past 12 months?

Artiva Biotherapeutics, Inc. lowest stock price was $1.47 and its highest was $17.31 in the past 12 months.

What is Artiva Biotherapeutics, Inc.’s market cap?

Artiva Biotherapeutics, Inc.’s market cap is $69.37M.

When is Artiva Biotherapeutics, Inc.’s upcoming earnings report date?

Artiva Biotherapeutics, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 80 days.

How were Artiva Biotherapeutics, Inc.’s earnings last quarter?

Artiva Biotherapeutics, Inc. released its earnings results on Aug 06, 2025. The company reported -$0.87 earnings per share for the quarter, missing the consensus estimate of -$0.806 by -$0.064.

Is Artiva Biotherapeutics, Inc. overvalued?

According to Wall Street analysts Artiva Biotherapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Artiva Biotherapeutics, Inc. pay dividends?

Artiva Biotherapeutics, Inc. does not currently pay dividends.

What is Artiva Biotherapeutics, Inc.’s EPS estimate?

Artiva Biotherapeutics, Inc.’s EPS estimate is -0.87.

How many shares outstanding does Artiva Biotherapeutics, Inc. have?

Artiva Biotherapeutics, Inc. has 24,425,762 shares outstanding.

What happened to Artiva Biotherapeutics, Inc.’s price movement after its last earnings report?

Artiva Biotherapeutics, Inc. reported an EPS of -$0.87 in its last earnings report, missing expectations of -$0.806. Following the earnings report the stock price went down -8.014%.

Which hedge fund is a major shareholder of Artiva Biotherapeutics, Inc.?

Currently, no hedge funds are holding shares in ARTV

Artiva Biotherapeutics, Inc. Stock Smart Score

Underperform

Fundamentals

Return on Equity

-86.18%

Trailing 12-Months

Asset Growth

123.14%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc. (ARTV) is a biotechnology company focused on the development and commercialization of innovative cellular therapies for cancer treatment. The company specializes in the research and development of off-the-shelf natural killer (NK) cell therapies designed to treat a variety of hematologic cancers and solid tumors. Artiva leverages its proprietary platform technology to enhance the efficacy, safety, and scalability of NK cell-based therapeutics, positioning itself at the forefront of next-generation cancer immunotherapies.

Artiva Biotherapeutics, Inc. (ARTV) Earnings & Revenues

Historic Earnings Reports

ARTV Stock 12 Month Forecast

Average Price Target

$16.00

▲(389.30% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","19":"$19","4.75":"$4.75","9.5":"$9.5","14.25":"$14.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.75,9.5,14.25,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.83,3.996923076923077,5.163846153846154,6.330769230769231,7.497692307692308,8.664615384615384,9.831538461538461,10.99846153846154,12.165384615384616,13.332307692307692,14.499230769230769,15.666153846153847,16.833076923076923,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.83,3.8430769230769233,4.8561538461538465,5.869230769230769,6.882307692307692,7.895384615384615,8.908461538461538,9.92153846153846,10.934615384615384,11.947692307692307,12.96076923076923,13.973846153846154,14.986923076923075,{"y":16,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.83,3.5353846153846153,4.240769230769231,4.946153846153846,5.651538461538461,6.356923076923077,7.062307692307693,7.7676923076923075,8.473076923076924,9.178461538461539,9.883846153846154,10.58923076923077,11.294615384615385,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.77,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.59,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.59,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.54,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.72,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.08,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.37,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >